NOEMI
MANCEÑIDO MARCOS
PROFESOR DOCTOR
![Foto de NOEMI](/img/nophoto.png)
![Foto de Hospital Clínico San Carlos de Madrid](/img/noimage_org.png)
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (13)
2024
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives
Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2021
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2020
-
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Scientific Reports, Vol. 10, Núm. 1
2019
-
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
Current Medical Research and Opinion, Vol. 35, Núm. 7, pp. 1297-1304
2018
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
2015
-
Incidence, management, and course of cancer in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333
2012
-
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523